Scholarlink

Objective <p>This study evaluated SQSTM1/p62 expression patterns and its prognostic value across multiple cancers, with a focus on nasopharyngeal carcinoma (NPC).</p> Results description <p>SQSTM1/p62 showed significantly higher mRNA and protein levels in tumors versus normal tissues across cancer types. High SQSTM1/p62 expression correlated with poorer OS and DSS in multiple cancers. Among 86 NPC patients (median follow-up 46.8&#xa0;months), high SQSTM1/p62 expression (69.8% vs CNP 45% in controls, <i>P</i> = 0.036) independently predicted reduced DSS (HR = 4.51, 95% CI: 1.40–14.52). The unadjusted and multivariable-adjusted models consistently revealed a stable relationship between SQSTM1/p62 expression and patient prognosis. No significant interaction was observed between SQSTM1/p62 expression and age, TNM stage, or treatment methods (induction chemotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy). In summary, elevated SQSTM1/p62 expression correlates with poor clinical outcomes in pancancer analyses and serves as an independent prognostic factor for NPC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

SQSTM1/p62 as a prognostic indicator in pancancer and nasopharyngeal carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月6日

查看全文
  • Li-li Chen,
  • Zong-yao Zhang,
  • Bo Wu,
  • Mei-zhen Lu

摘要

Objective

This study evaluated SQSTM1/p62 expression patterns and its prognostic value across multiple cancers, with a focus on nasopharyngeal carcinoma (NPC).

Results description

SQSTM1/p62 showed significantly higher mRNA and protein levels in tumors versus normal tissues across cancer types. High SQSTM1/p62 expression correlated with poorer OS and DSS in multiple cancers. Among 86 NPC patients (median follow-up 46.8 months), high SQSTM1/p62 expression (69.8% vs CNP 45% in controls, P = 0.036) independently predicted reduced DSS (HR = 4.51, 95% CI: 1.40–14.52). The unadjusted and multivariable-adjusted models consistently revealed a stable relationship between SQSTM1/p62 expression and patient prognosis. No significant interaction was observed between SQSTM1/p62 expression and age, TNM stage, or treatment methods (induction chemotherapy, concurrent chemoradiotherapy, adjuvant chemotherapy). In summary, elevated SQSTM1/p62 expression correlates with poor clinical outcomes in pancancer analyses and serves as an independent prognostic factor for NPC.